NCT02893254已完成3 期
A Multicenter, Randomized, Double-blind, Parallel-controlled Phase 3 Study Evaluating the Efficacy and Safety of Recombinant Human Monoclonal Antibody Against Human Tumor Necrosis Factor-α (IBI303) Compared to Adalimumab in Patients With Active Ankylosing Spondylitis
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 438
- 主要终点
- Number of participants meeting the Assessment of Spondyloarthritis International Society(ASAS) ASAS20 Response Criteria
研究概览
简要总结
Study of the efficacy and safety of IBI303 compared with adalimumab in adult patients with ankylosing spondylitis (AS) who have had an inadequate response to or who are intolerant to one or more nonsteroidal anti-inflammatory drugs (NSAIDs)
详细描述
Adults patients with active ankylosing spondylitis (AS) were randomized in a 1:1 ratio to receive treatment with adalimumab 40 mg every other week (eow) or IBI303, given subcutaneously (SC), in the 24-week double-blind (DB) phase. Randomized participants received one SC injection of the appropriate DB study medication (adalimumab 40 mg or IBI303) at Week 0 and then eow until Week 22. A follow-up visit occurred 70 days(Week 32) after the last dose of study drug to obtain information on any ongoing or new adverse events (AEs).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Between 18 and 65 years of age
- •Fulfilled modified New York Criteria for AS, had active disease（as defined by≥2 of the following: Bath AS Disease Activity Index(BASDAI) ≥4(10cm VAS); total back pain≥40(100mm VAS) and ≥1 hour of morning stiffness）
- •No response, or inadequate response, or intolerant to≥1 NSAID at least 4 weeks
- •Participants who are regularly taking DMARDs(SSZ≤3g/day，MTX≤15mg/week) as part of their AS therapy are required to be on a stable dose ≥28 days prior to Baseline, and are required to be on a stable DMARDs dose and to accept oral folic acid therapy(≥5mg/week) during the study period；
- •Participants who are regularly taking NSAIDs as part of their AS therapy are required to be on a stable dose ≥14 days prior to Baseline, and are required to be on a stable dose during the study period；
- •Glucocorticoid must be withdrawn for at least 4 weeks prior to Baseline, and were not allowed during the study period.
- •Total duration of prior physical therapy should be at least 2 weeks
- •Traditional Chinese medicines to AS must be withdrawn for at least 28 days prior to Baseline, and were not allowed during the study period.
- •Biological agents must be withdrawn: etanercept and anakinra(IL-1 receptor antagonist) for at least 4 weeks prior to administration; tocilizumab(IL-6 monoclonal antibody) for at least 12 weeks prior to administration; other biological agents for 12 weeks or 5 half-lives(whichever is longer) prior to administration
- •Male subjects' partner, or female subjects should be willing to use adequate contraception from admission to clinical research center until 5 months post dosing；
- •To fully understanding the purpose of the study, to understand the pharmacological action of the study drugs and the possible adverse reactions; participants who are voluntary to sign the informed consent according to the Declaration of Helsinki
- •Blood routine examination: hemoglobin ≥90g/L, WBC count ≥3.5×109/L, PLT count ≥100×109/L; liver function examination: total bilirubin(TBIL), direct bilirubin(DBIL), aspartate transaminase(AST) or alanine aminotransferase (ALT) <1.5×ULN; kidney function examination：creatinine(Cr) ≤ULM, usea nitrogen(BUN) ≤1.25×ULN
排除标准
- •No response to prior tumor necrosis factor-α inhibitors treatment
- •Use of DMARD(except for sulfasalazine or methotrexate) within 4 weeks prior to Baseline
- •Use of opioid analgesics(such as methadone, morphine) within 4 weeks prior to Baseline
- •X-ray suggests total spinal ankylosis, or sacroiliac joint fusion
- •Patients with moderate to severe congestive heart failure（NYHA ）
- •Has received intra-articular joint injection(s), spinal or paraspinal injection(s) with corticosteroids within 28 days prior to Baseline
- •Has undergone spinal surgery or joint surgery within 2 months prior to the administration of the study drugs
- •Patients with other rheumatic diseases or immunodeficiency, including inflammatory bowel disease(IBD), psoriasis, active uveitis
- •Recent active or chronic infection requiring anti-infective therapy, such as M.tuberculosis, Listeriosis, Histophasmosis
- •Tuberculosis(TB) history, or a positive T-SPOT test, or chest radiograph suggests active TB
- •Positive serology for human immunodeficiency virus(HIV) antibody
- •Positive serology for hepatitis C virus antibody
- •Active or chronic HBV infection, such as positive hepatitis B virus surface antigen
- •Malignancy history ≤5 years（except for successfully treated cutaneous squamous cell carcinoma, or basal cell carcinoma, or localized cervical carcinoma in situ, or breast ductal carcinoma in situ）
- •History of relevant allergy/hypersensitivity (including allergy to the study medications or its excipients)
- •Prior or recent central nervous system demyelinating disease or multiple sclerosis
- •Use of live vaccines within 3 months prior to Baseline
- •Pregnant or breastfeeding women
- •Suspected or confirmed drug/alcohol use
- •Participation in another interventional trial within 3 months prior to administration
- •Subjects with serious psychiatric or nervous system diseases, or patients who have difficulty in informing consent or AE presentation, or illiterate patients
- •Subjects who are unable to complete the study, or who may not be able to comply with the requirement of the study, judged by the investigators
研究组 & 干预措施
IBI303
Experimental
IBI303 40mg administered subcutaneously every other week, 12cycles
干预措施: IBI303 (Drug)
Adalimumab
Active Comparator
Adalimumab 40mg administered subcutaneously every other week
干预措施: Adalimumab (Drug)
结局指标
主要结局
Number of participants meeting the Assessment of Spondyloarthritis International Society(ASAS) ASAS20 Response Criteria
时间窗: Week 24
次要结局
- Number of Participants Meeting the ASAS5/6 Response Criteria(Week 20)
- Change from Baseline in ASDAS-CRP and ASDAS-ESR(Baseline and Week 24)
- Number of participants meeting the ASAS20 Response(Week 20)
- Number of participants meeting the ASAS40 Response Criteria(Week20)
- Change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index(BASDAI), in Bath Ankylosing Spondylitis Functional Index(BASFI), in Bath Ankylosing Spondylitis Messure Index(BASMI)(Baseline and Week 20)
- Change from Baseline in Patient Global Assessment of Disease Activity(Baseline and Week 24)
- Number of Participants Meeting the ASAS Partial Remission(Week 20)
- Change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index(BASDAI), in Bath Ankylosing Spondylitis Functional Index(BASFI), in Bath Ankylosing Spondylitis Measure Index(BASMI)(Baseline and Week 24)
- Change from Baseline in Total Back Pain Score(Baseline and Week 24)
- Change From Baseline in Inflammation Score(Baseline and Week 24)
- Change from Baseline in Maastricht Ankylosing Spondylitis Enthesis Score(MASES)(Baseline and Week 24)
- Change from Baseline in EQ-5D/WPAI-SHP/HAQ-S QoL(Baseline and Week 24)
研究者
相似试验
已完成
3 期
Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque PsoriasisPsoriasisNCT01970488Amgen350
已完成
3 期
Efficacy and Safety of Adalimumab in Subjects With Inactive UveitisUveitisNCT01124838AbbVie (prior sponsor, Abbott)261
已完成
3 期
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque PsoriasisChronic Plaque PsoriasisModerate to Severe Plaque PsoriasisNCT03412747UCB Biopharma SRL478
进行中（未招募）
1 期
Efficacy and Safety of IBI310 Combined With Sintilimab in Patients With Advanced Hepatocellular CarcinomaAdvanced Hepatocellular CarcinomaNCT04401813Innovent Biologics (Suzhou) Co. Ltd.97
招募中
1 期
IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract CancerAdvanced Biliary Tract CancerNCT05653180Innovent Biologics (Suzhou) Co. Ltd.20